Session

Oligometastatic cancer: Yet another disease stage?

Joint meeting of the EAU Section of Urological Imaging (ESUI), the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

  • Location:
    Room 14a (ICM, Level 1)
  • Chairs:
     K. Junker, Homburg (DE)
     R. Montironi, Ancona (IT)
     J. Walz, Marseille (FR)
  • Aims and objectives of this session

    Metastases to lymph nodes (LNs) represent an unfavorable prognostic factor in patients with prostate cancer. The metastatic detection rate can vary according to the approach adopted in the microscopic analysis, which includes frozen section examination, total inclusion of the tissue with and without whole mount sections, serial sectioning, and application of immunohistochemistry. The aims & objectives for this session are an update on the histopathological evaluation of LND specimens, and focus is made on their clinical and prognostic significance.

Introduction
 
 K. Junker, Homburg (DE)
 
 R. Montironi, Ancona (IT)
 
 J. Walz, Marseille (FR)
What is oligometastic disease?
 
Moderators:
 H.U. Ahmed, London (GB)
 
 
 A. Bjartell, Malmö (SE)
 
 
 R. Montironi, Ancona (IT)
Metastatic disease equals non metastatic disease: Definition of oligometastatic disease
 A. Briganti, Milan (IT)
Discussion
Why should we consider oligometastatic disease as a different disease stage?
 G. De Meerleer, Ghent (BE)
Discussion
The "dormant" metastasis: Myth or truth?
 L.R. Languino, Philadelphia (US)
Discussion
Exosomes in metastatic urological cancers: What is their prognostic meaning?
 G. Jenster, Rotterdam (NL)
Discussion
Was PET imaging the door opener for oligometastatic disease?
 J. Walz, Marseille (FR)
Discussion
Hype or true need ? The EAU Guidelines Office point of view on oligometastatic cancer
 J. N'Dow, Aberdeen (GB)
Discussion
Oligometastatic bladder cancer
 
Moderators:
To be confirmed
 
 
 M. Knowles, Leeds (GB)
 
 
 J. Walz, Marseille (FR)
Case of oligometastic bladder cancer
 F. Algaba, Barcelona (ES)
Discussion
How to detect oligometastatic bladder cancer with imaging?
 L.S. Mertens, Amsterdam (NL)
Discussion
Prognostic factors in metastatic bladder cancer
 R. Knüchel Clarke, Aachen (DE)
Discussion
Treatment options for oligometastatic bladder cancer
 P. Gontero, Turin (IT)
Discussion
ESUI Vision Award 2016
Oligometastatic renal cell cancer
 
Moderators:
 Y. Allory, Creteil (FR)
 
 
 K. Junker, Homburg (DE)
 
 
 S. Siracusano, Trieste (IT)
Case of oligometastic renal cell cancer
 Y. Allory, Creteil (FR)
Discussion
How to detect oligometastatic renal cell cancer with imaging?
 O. Boerman, Nijmegen (NL)
Discussion
Prognostic factors for oligometastatic renal cancer

To be confirmed

Discussion
Scientific basis for treatment options for oligometastatic renal cell cancer
 G. Yousef , Toronto (CA)
Discussion
Oligometastatic prostate cancer
 
Moderators:
 S. Bettuzzi, Parma (IT)
 
 
 T. Loch, Flensburg (DE)
 
 
 S. Perner, Lübeck (DE)
Case of oligometastic prostate cancer
 R. Montironi, Ancona (IT)
Discussion
How to detect oligometastatic prostate cancer with imaging?
 R. Schiavina, Bologna (IT)
Discussion
Prognosticators of metastatic prostate cancer: Genetic alterations as predictors of treatment of oligometastatic prostate cancer
 G.S. Bova, Tampere (FI)
Discussion
Treatment options for metastatic prostate cancer, resistance and perspectives
 M. Saar, Homburg (DE)
Discussion
Summary
 
 K. Junker, Homburg (DE)
 
 R. Montironi, Ancona (IT)
 
 J. Walz, Marseille (FR)